Discounted Cash Flow
Amphastar Pharmaceuticals, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $255.2m | $10.5m | $17.2m | 4.1% | $0.23 |
| 2017 | $240.2m (-5.9%) | $4.5m (-57.2%) | $4.1m (-76.1%) | 1.9% (-54.5%) | $0.10 (-56.5%) |
| 2018 | $294.7m (22.7%) | $-5.7m (-227.3%) | $-8.6m (-309.7%) | -1.9% (-203.7%) | $-0.12 (-220.0%) |
| 2019 | $322.4m (9.4%) | $48.9m (952.9%) | $207.0k (102.4%) | 15.2% (879.6%) | $1.04 (966.7%) |
| 2020 | $349.8m (8.5%) | $1.4m (-97.1%) | $23.4m (11209.7%) | 0.4% (-97.4%) | $0.03 (-97.1%) |
| 2021 | $437.8m (25.1%) | $62.1m (4327.4%) | $70.5m (201.3%) | 14.2% (3438.2%) | $1.30 (4233.3%) |
| 2022 | $499.0m (14.0%) | $91.4m (47.1%) | $65.1m (-7.6%) | 18.3% (29.1%) | $1.88 (44.6%) |
| 2023 | $644.4m (29.1%) | $137.5m (50.5%) | $145.3m (123.1%) | 21.3% (16.5%) | $2.85 (51.6%) |
| 2024 | $732.0m (13.6%) | $159.5m (16.0%) | $172.3m (18.6%) | 21.8% (2.1%) | $3.29 (15.4%) |
| 2025 | $719.9m (-1.7%) | $98.1m (-38.5%) | $121.2m (-29.7%) | 13.6% (-37.5%) | $2.10 (-36.2%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.